Litcius/Paper detail

Codelivery of anti-CD47 antibody and chlorin e6 using a dual pH-sensitive nanodrug for photodynamic immunotherapy of osteosarcoma

JIJIE XIAO, Hong Xiao, YUJUN CAI, J Liao, JUE LIU, LIN YAO, SHAOLIN LI

2023Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics13 citationsDOIOpen Access PDF

Abstract

Osteosarcoma is a malignant tumor originating from bone tissue that progresses rapidly and has a poor patient prognosis. Immunotherapy has shown great potential in the treatment of osteosarcoma. However, the immunosuppressive microenvironment severely limits the efficacy of osteosarcoma treatment. The dual pH-sensitive nanocarrier has emerged as an effective antitumor drug delivery system that can selectively release drugs into the acidic tumor microenvironment. Here, we prepared a dual pH-sensitive nanocarrier, loaded with the photosensitizer Chlorin e6 (Ce6) and CD47 monoclonal antibodies (aCD47), to deliver synergistic photodynamic and immunotherapy of osteosarcoma. On laser irradiation, Ce6 can generate reactive oxygen species (ROS) to kill cancer cells directly and induces immunogenic tumor cell death (ICD), which further facilitates the dendritic cell maturation induced by blockade of CD47 by aCD47. Moreover, both calreticulin released during ICD and CD47 blockade can accelerate phagocytosis of tumor cells by macrophages, promote antigen presentation, and eventually induce T lymphocyte-mediated antitumor immunity. Overall, the dual pH-sensitive nanodrug loaded with Ce6 and aCD47 showed excellent immune-activating and anti-tumor effects in osteosarcoma, which may lay the theoretical foundation for a novel combination model of osteosarcoma treatment.

Topics & Concepts

OsteosarcomaCancer researchTumor microenvironmentImmunotherapyNanocarriersImmunogenic cell deathCD47Immune systemPhotodynamic therapyCancer immunotherapyMedicineImmunologyChemistryPharmacologyOrganic chemistryDrugNanoplatforms for cancer theranosticsPhagocytosis and Immune RegulationImmunotherapy and Immune Responses